Tumor-specific transcriptional targeting of suicide gene therapy

J. Qiao, M. Doubrovin, B. V. Sauter, Y. Huang, Z. S. Guo, J. Balatoni, T. Akhurst, R. G. Blasberg, J. G. Tjuvajev, S. H. Chen, S. L.C. Woo

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Transcriptional targeting of gene expression has been plagued by the weakness of tissue-specific promoters. Thus, to increase promoter strength while maintaining tissue specificity, we constructed a recombinant adenovirus containing a binary promoter system with a tumor-specific promoter (CEA; carcinoembryonic antigen) driving a transcription transactivator, which then activates a minimal promoter to express a suicide gene (HSV-tk; herpes simplex virus thymidine kinase). This ADV/binary-tk induced equal or greater cell killing in a CEA-specific manner in vitro compared with the CEA-independent killing of a vector with a constitutive viral promoter driving HSV-tk (ADV/RSV-tk). To monitor adenovirus-mediated HSV-tk gene expression in vivo, we employed noninvasive nuclear imaging using a radioiodinated nucleoside analog ([131I]-FIAU) serving as a substrate for HSV-tk. [131I]-FIAU-derived radioactivity accumulated after intratumoral injection of ADV/binary-tk only in the area of CEA-positive tumors with significantly less spread to the adjacent liver tissue than after administration of the universally expressed ADV/RSV-tk. Both viruses exhibited similar antitumor efficacy upon injection of liver metastases. Importantly, in vivo dose escalation studies demonstrated significantly reduced toxicity after intravenous administration of ADV/binary-tk versus ADV/RSV-tk. In summary, the increased therapeutic index of this novel, amplified CEA-driven suicide gene therapy vector is a proof of principle for the powerful enhancement of a weak tissue-specific promoter for effective tumor restricted gene expression.

Original languageEnglish (US)
Pages (from-to)168-175
Number of pages8
JournalGene Therapy
Volume9
Issue number3
DOIs
StatePublished - Jan 1 2002

Fingerprint

Genetic Therapy
Suicide
Gene Expression
Adenoviridae
Carcinogens
Neoplasms
Organ Specificity
Injections
Trans-Activators
Thymidine Kinase
Liver
Carcinoembryonic Antigen
Simplexvirus
Nucleosides
Intravenous Administration
Radioactivity
Neoplasm Metastasis
Viruses
Genes
fialuridine

Keywords

  • Adenovirus
  • Imaging
  • Liver metastases
  • Suicide gene therapy
  • Transcriptional targeting

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Qiao, J., Doubrovin, M., Sauter, B. V., Huang, Y., Guo, Z. S., Balatoni, J., ... Woo, S. L. C. (2002). Tumor-specific transcriptional targeting of suicide gene therapy. Gene Therapy, 9(3), 168-175. https://doi.org/10.1038/sj/gt/3301618

Tumor-specific transcriptional targeting of suicide gene therapy. / Qiao, J.; Doubrovin, M.; Sauter, B. V.; Huang, Y.; Guo, Z. S.; Balatoni, J.; Akhurst, T.; Blasberg, R. G.; Tjuvajev, J. G.; Chen, S. H.; Woo, S. L.C.

In: Gene Therapy, Vol. 9, No. 3, 01.01.2002, p. 168-175.

Research output: Contribution to journalArticle

Qiao, J, Doubrovin, M, Sauter, BV, Huang, Y, Guo, ZS, Balatoni, J, Akhurst, T, Blasberg, RG, Tjuvajev, JG, Chen, SH & Woo, SLC 2002, 'Tumor-specific transcriptional targeting of suicide gene therapy', Gene Therapy, vol. 9, no. 3, pp. 168-175. https://doi.org/10.1038/sj/gt/3301618
Qiao J, Doubrovin M, Sauter BV, Huang Y, Guo ZS, Balatoni J et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Therapy. 2002 Jan 1;9(3):168-175. https://doi.org/10.1038/sj/gt/3301618
Qiao, J. ; Doubrovin, M. ; Sauter, B. V. ; Huang, Y. ; Guo, Z. S. ; Balatoni, J. ; Akhurst, T. ; Blasberg, R. G. ; Tjuvajev, J. G. ; Chen, S. H. ; Woo, S. L.C. / Tumor-specific transcriptional targeting of suicide gene therapy. In: Gene Therapy. 2002 ; Vol. 9, No. 3. pp. 168-175.
@article{464c7c813cd54d8281fe1a0d1c7cde90,
title = "Tumor-specific transcriptional targeting of suicide gene therapy",
abstract = "Transcriptional targeting of gene expression has been plagued by the weakness of tissue-specific promoters. Thus, to increase promoter strength while maintaining tissue specificity, we constructed a recombinant adenovirus containing a binary promoter system with a tumor-specific promoter (CEA; carcinoembryonic antigen) driving a transcription transactivator, which then activates a minimal promoter to express a suicide gene (HSV-tk; herpes simplex virus thymidine kinase). This ADV/binary-tk induced equal or greater cell killing in a CEA-specific manner in vitro compared with the CEA-independent killing of a vector with a constitutive viral promoter driving HSV-tk (ADV/RSV-tk). To monitor adenovirus-mediated HSV-tk gene expression in vivo, we employed noninvasive nuclear imaging using a radioiodinated nucleoside analog ([131I]-FIAU) serving as a substrate for HSV-tk. [131I]-FIAU-derived radioactivity accumulated after intratumoral injection of ADV/binary-tk only in the area of CEA-positive tumors with significantly less spread to the adjacent liver tissue than after administration of the universally expressed ADV/RSV-tk. Both viruses exhibited similar antitumor efficacy upon injection of liver metastases. Importantly, in vivo dose escalation studies demonstrated significantly reduced toxicity after intravenous administration of ADV/binary-tk versus ADV/RSV-tk. In summary, the increased therapeutic index of this novel, amplified CEA-driven suicide gene therapy vector is a proof of principle for the powerful enhancement of a weak tissue-specific promoter for effective tumor restricted gene expression.",
keywords = "Adenovirus, Imaging, Liver metastases, Suicide gene therapy, Transcriptional targeting",
author = "J. Qiao and M. Doubrovin and Sauter, {B. V.} and Y. Huang and Guo, {Z. S.} and J. Balatoni and T. Akhurst and Blasberg, {R. G.} and Tjuvajev, {J. G.} and Chen, {S. H.} and Woo, {S. L.C.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1038/sj/gt/3301618",
language = "English (US)",
volume = "9",
pages = "168--175",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Tumor-specific transcriptional targeting of suicide gene therapy

AU - Qiao, J.

AU - Doubrovin, M.

AU - Sauter, B. V.

AU - Huang, Y.

AU - Guo, Z. S.

AU - Balatoni, J.

AU - Akhurst, T.

AU - Blasberg, R. G.

AU - Tjuvajev, J. G.

AU - Chen, S. H.

AU - Woo, S. L.C.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Transcriptional targeting of gene expression has been plagued by the weakness of tissue-specific promoters. Thus, to increase promoter strength while maintaining tissue specificity, we constructed a recombinant adenovirus containing a binary promoter system with a tumor-specific promoter (CEA; carcinoembryonic antigen) driving a transcription transactivator, which then activates a minimal promoter to express a suicide gene (HSV-tk; herpes simplex virus thymidine kinase). This ADV/binary-tk induced equal or greater cell killing in a CEA-specific manner in vitro compared with the CEA-independent killing of a vector with a constitutive viral promoter driving HSV-tk (ADV/RSV-tk). To monitor adenovirus-mediated HSV-tk gene expression in vivo, we employed noninvasive nuclear imaging using a radioiodinated nucleoside analog ([131I]-FIAU) serving as a substrate for HSV-tk. [131I]-FIAU-derived radioactivity accumulated after intratumoral injection of ADV/binary-tk only in the area of CEA-positive tumors with significantly less spread to the adjacent liver tissue than after administration of the universally expressed ADV/RSV-tk. Both viruses exhibited similar antitumor efficacy upon injection of liver metastases. Importantly, in vivo dose escalation studies demonstrated significantly reduced toxicity after intravenous administration of ADV/binary-tk versus ADV/RSV-tk. In summary, the increased therapeutic index of this novel, amplified CEA-driven suicide gene therapy vector is a proof of principle for the powerful enhancement of a weak tissue-specific promoter for effective tumor restricted gene expression.

AB - Transcriptional targeting of gene expression has been plagued by the weakness of tissue-specific promoters. Thus, to increase promoter strength while maintaining tissue specificity, we constructed a recombinant adenovirus containing a binary promoter system with a tumor-specific promoter (CEA; carcinoembryonic antigen) driving a transcription transactivator, which then activates a minimal promoter to express a suicide gene (HSV-tk; herpes simplex virus thymidine kinase). This ADV/binary-tk induced equal or greater cell killing in a CEA-specific manner in vitro compared with the CEA-independent killing of a vector with a constitutive viral promoter driving HSV-tk (ADV/RSV-tk). To monitor adenovirus-mediated HSV-tk gene expression in vivo, we employed noninvasive nuclear imaging using a radioiodinated nucleoside analog ([131I]-FIAU) serving as a substrate for HSV-tk. [131I]-FIAU-derived radioactivity accumulated after intratumoral injection of ADV/binary-tk only in the area of CEA-positive tumors with significantly less spread to the adjacent liver tissue than after administration of the universally expressed ADV/RSV-tk. Both viruses exhibited similar antitumor efficacy upon injection of liver metastases. Importantly, in vivo dose escalation studies demonstrated significantly reduced toxicity after intravenous administration of ADV/binary-tk versus ADV/RSV-tk. In summary, the increased therapeutic index of this novel, amplified CEA-driven suicide gene therapy vector is a proof of principle for the powerful enhancement of a weak tissue-specific promoter for effective tumor restricted gene expression.

KW - Adenovirus

KW - Imaging

KW - Liver metastases

KW - Suicide gene therapy

KW - Transcriptional targeting

UR - http://www.scopus.com/inward/record.url?scp=0036187890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036187890&partnerID=8YFLogxK

U2 - 10.1038/sj/gt/3301618

DO - 10.1038/sj/gt/3301618

M3 - Article

C2 - 11859419

AN - SCOPUS:0036187890

VL - 9

SP - 168

EP - 175

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 3

ER -